First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: ADMA Biologics: the story is balanced — ASCENIV prescription volume growth and market share gains in the PIDD segment (estimated 15,000 PIDD patients in US…
growth - The 65% revenue growth, 800% net income growth, and 54% ROE attract growth investors seeking high-margin biotech scalability…
Rising interest rates have minimal direct operational impact given ADMA's low debt load (0.19 D/E ratio) and positive operating cash flow.
Watch on earnings: Quarterly ASCENIV revenue growth rate and market share versus total US IVIG market (estimated $4-5B annually), Gross margin trajectory toward 60%+ target as manufacturing utilization approaches 80-90% of capacity, Plasma collection volumes per center and donor retention rates (industry average 30-40% annual donor attrition).
One Sentence Summary:
ADMA Biologics: the story is balanced — asceniv prescription volume growth and market share gains in the pidd segment (estimated 15,000 pidd patients in us, growing 3-5% annually).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.